CORDIS
EU research results

CORDIS

English EN

European (euro) network for development of novel safe vaccines based on new generation amplicons (amp) and other defective hsv-1 derived vectors as foreign antigen delivery systems.

Project information

Grant agreement ID: QLK2-CT-1999-00055

  • Start date

    1 February 2000

  • End date

    1 August 2003

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 1 765 621

  • EU contribution

    € 1 765 621

Coordinated by:

UNIVERSITE CLAUDE BERNARD LYON 1

France

Objective

Seven European laboratories have associated to evaluate the potential of defective HSV vectors, including helper-free HSV amplicons, as vaccine for the delivery of foreign antigens. The model antigens will be derived from human viruses of high public health concern, such as HCV, HIV-1 and HPV-16, each causing significant morbidity and mortality and substantial economic burden. No effective vaccines are available to prevent or treat these viral infections. To this end we plan to determine the conditions required to optimise delivery, expression and presentation of foreign antigens, including the in vivo synthesis of empty virus-like HCV and HPV-16 particles. Significant innovations will be the use of a unique in its nature vector (the amplicon), never used before, as vaccine vector and the attempt to manipulate the immune response by attracting monocytes to sites of infection and inducing their differentiation into dendritic cells.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITE CLAUDE BERNARD LYON 1

Address

43,Boulevard Du 11 Novembre 1918, 43
69622 Villeurbanne

France

Participants (5)

GERMAN CANCER RESEARCH CENTER

Germany

HELLENIC PASTEUR INSTITUTE

Greece

LUDWIG-MAXIMILIANS UNIVERSITY OF MUNICH

Germany

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

UNIVERSITÀ DEGLI STUDI DI FERRARA

Italy

Project information

Grant agreement ID: QLK2-CT-1999-00055

  • Start date

    1 February 2000

  • End date

    1 August 2003

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 1 765 621

  • EU contribution

    € 1 765 621

Coordinated by:

UNIVERSITE CLAUDE BERNARD LYON 1

France